ASCENDIS PHARMA A/S INCORPORATION BY REFERENCE
This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576,333-203040,333-210810,333-211512,333-213412,333-214843,333-216883,333-254101 and 333-261550) and Form F-3 (Registration Numbers 333-209336,333-211511,333-216882,333-223134,333-225284 and 333-256571) of Ascendis Pharma A/S (the "Company") (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.
On December 5, 2022, the Company announced that the U.S. Food & Drug Administration has allowed the Company to initiate an expanded access program for its investigational parathyroid hormone replacement therapy, TransCon PTH (palopegteriparatide), for adult patients with hypoparathyroidism.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Ascendis Pharma A/S published this content on 05 December 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 December 2022 13:11:03 UTC.
